Clinical Trial Update: Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment [Phase 1]

View source ↗

Summary

Phase 1 trial to assess the safety of the anti-cancer drugs tazemetostat and belinostat in patients with recurrent or refractory lymphomas; the study is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Non-hodgkin Lymphoma
• T-cell Non-hodgkin Lymphoma
• Transformed Non-hodgkin Lymphoma

Drugs mentioned

• BELEODAQ (BELINOSTAT)
• TAZVERIK (TAZEMETOSTAT)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | Phase 1 | Status: ACTIVE_NOT_RECRUITING